|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6077835A
(en)
|
1994-03-23 |
2000-06-20 |
Case Western Reserve University |
Delivery of compacted nucleic acid to cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
KR970029803A
(ko)
|
1995-11-03 |
1997-06-26 |
김광호 |
반도체 메모리장치의 프리차지 회로
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6355271B1
(en)
|
1999-02-03 |
2002-03-12 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
|
US6281005B1
(en)
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
|
US20100081792A1
(en)
|
2001-06-28 |
2010-04-01 |
Smithkline Beecham Corporation |
Ligand
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
AU2003270426A1
(en)
|
2002-09-12 |
2004-04-30 |
Avanir Pharmaceuticals |
PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
|
|
KR100944575B1
(ko)
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Ｃｄ20에 대한 인간 모노클로날 항체
|
|
CA2531118C
(en)
|
2003-07-01 |
2013-01-08 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
US7741568B2
(en)
|
2005-01-13 |
2010-06-22 |
The Wiremold Company |
Downward facing receptacle assembly for cable raceway
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
AU2006291005A1
(en)
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-CD3 antibody formulations
|
|
US8236308B2
(en)
|
2005-10-11 |
2012-08-07 |
Micromet Ag |
Composition comprising cross-species-specific antibodies and uses thereof
|
|
KR101866623B1
(ko)
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 １가 항체 및 그의 제조 방법
|
|
EA015992B1
(ru)
|
2006-03-17 |
2012-01-30 |
Байоджен Айдек Эмэй Инк. |
Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
EP2626372B1
(en)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
KR101540823B1
(ko)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
EP2615175B1
(en)
|
2007-05-31 |
2018-08-08 |
Genmab A/S |
Monovalent human antibodies
|
|
WO2008145141A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
|
CA2689895A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Non-glycosylated recombinant monovalent antibodies
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
EP2535350B1
(en)
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
|
AU2008304111B2
(en)
|
2007-09-27 |
2014-04-24 |
Amgen Inc. |
Pharmaceutical formulations
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
JP2009212059A
(ja)
|
2008-03-06 |
2009-09-17 |
Toshiba Corp |
電動軽車両のバッテリ装置
|
|
WO2010015792A1
(en)
|
2008-08-06 |
2010-02-11 |
Argenta Discovery Limited |
Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
|
|
JP5397668B2
(ja)
|
2008-09-02 |
2014-01-22 |
ソニー株式会社 |
記憶素子および記憶装置
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
|
AU2010229705A1
(en)
|
2009-03-27 |
2011-10-20 |
Zymogenetics, Inc. |
Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CN102711810B
(zh)
|
2009-11-30 |
2015-04-22 |
詹森生物科技公司 |
效应子功能已消除的抗体Fc区突变体
|
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
WO2012023053A2
(en)
|
2010-08-16 |
2012-02-23 |
Novimmune S.A. |
Methods for the generation of multispecific and multivalent antibodies
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
BR112013002167A2
(pt)
|
2010-08-24 |
2016-05-31 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
WO2012162067A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
CN102250246A
(zh)
|
2011-06-10 |
2011-11-23 |
常州亚当生物技术有限公司 |
抗VEGF/PDGFRβ双特异性抗体及其应用
|
|
LT2748201T
(lt)
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
|
IN2014CN03887A
(enExample)
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
WO2013123114A2
(en)
|
2012-02-16 |
2013-08-22 |
Santarus, Inc. |
Antibody formulations
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
DK2869845T3
(da)
|
2012-07-06 |
2019-12-09 |
Genmab Bv |
Dimert protein med tredobbelte mutationer
|
|
WO2014006217A1
(en)
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
DK2924052T3
(da)
|
2012-11-21 |
2019-09-30 |
Pharmabcine Inc |
Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
|
|
WO2014131694A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN104936985A
(zh)
|
2013-02-26 |
2015-09-23 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
|
KR102813816B1
(ko)
|
2013-07-05 |
2025-05-29 |
젠맵 에이/에스 |
인간화 또는 키메라 cd3 항체
|
|
BR112016000666A2
(pt)
|
2013-07-12 |
2017-10-03 |
Zymeworks Inc |
Constructos de ligação de antígeno cd3 e cd19 biespecíficos
|
|
FR3008667B1
(fr)
|
2013-07-19 |
2015-09-04 |
Bosch Gmbh Robert |
Unite de commande de freinage
|
|
HUE050159T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
WO2015121318A1
(en)
|
2014-02-12 |
2015-08-20 |
Sanofi |
Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
US20170128448A1
(en)
|
2014-07-11 |
2017-05-11 |
Celgene Corporation |
Combination therapy for cancer
|
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
CN104922668B
(zh)
|
2014-12-10 |
2019-08-23 |
信达生物制药(苏州)有限公司 |
一种稳定的抗vegf抗体制剂及其用途
|
|
CN107660214B
(zh)
|
2015-01-08 |
2022-02-08 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
|
US20160199399A1
(en)
|
2015-01-09 |
2016-07-14 |
Medical Prognosis Institute A/S |
Methods for predicting drug responsiveness in cancer patients
|
|
CN104922688A
(zh)
|
2015-02-10 |
2015-09-23 |
昆明贵研药业有限公司 |
奥沙利铂的环糊精复合物及制备方法
|
|
EP3892302B8
(en)
|
2015-04-06 |
2023-10-18 |
Janssen Pharmaceutica NV |
Compositions containing ibrutinib
|
|
FI3322727T3
(fi)
*
|
2015-07-15 |
2026-03-17 |
Genmab As |
Humanisoituja tai kimeerisiä CD3-vasta-aineita
|
|
CN108602889A
(zh)
*
|
2015-12-22 |
2018-09-28 |
瑞泽恩制药公司 |
医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
|
|
IL304871A
(en)
|
2016-01-11 |
2023-10-01 |
Inhibrx Inc |
Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
EP3411401A1
(en)
|
2016-02-03 |
2018-12-12 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
WO2017210485A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
|
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
AU2018259078B2
(en)
|
2017-04-27 |
2021-10-07 |
Astrazeneca Ab |
C5-anilinoquinazoline compounds and their use in treating cancer
|
|
JP7009517B2
(ja)
|
2017-06-21 |
2022-01-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
|
|
US11472880B2
(en)
|
2017-08-14 |
2022-10-18 |
Morphosys Ag |
Humanized antibodies for CD3
|
|
BR112020015052A2
(pt)
|
2018-02-09 |
2020-12-08 |
Genmab A/S |
Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
|
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
|
BR112020023508A2
(pt)
|
2018-05-24 |
2021-03-30 |
Janssen Biotech, Inc. |
Anticorpos anti-cd3 e usos dos mesmos
|
|
BR112021008486A2
(pt)
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
|
EP4427810A3
(en)
|
2018-11-30 |
2024-12-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
AU2020328195A1
(en)
|
2019-08-15 |
2022-03-03 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses
|
|
US20230143066A1
(en)
|
2020-04-17 |
2023-05-11 |
Ono Pharmaceutical Co., Ltd. |
Method for removing color from drug substance of protein preparation
|
|
KR20230008775A
(ko)
*
|
2020-05-08 |
2023-01-16 |
젠맵 에이/에스 |
Cd3 및 cd20에 대한 이중특이적 항체
|
|
JP2023539525A
(ja)
|
2020-09-02 |
2023-09-14 |
ジェンマブ エー／エス |
抗体療法
|
|
JP2023542290A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
WO2022053654A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
IL301086A
(en)
*
|
2020-09-10 |
2023-05-01 |
Genmab As |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
WO2022053657A1
(en)
*
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
CN116437956A
(zh)
*
|
2020-09-10 |
2023-07-14 |
健玛保 |
用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
|
|
BR112023004319A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma difuso de grandes células b
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
CA3243415A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 in a polytherapy regimen for the treatment of diffuse large B-cell lymphoma
|
|
KR20240144239A
(ko)
|
2022-01-28 |
2024-10-02 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
IL319999A
(en)
|
2022-11-02 |
2025-06-01 |
Genmab As |
Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome
|
|
EP4695293A1
(en)
|
2023-04-13 |
2026-02-18 |
Genmab A/S |
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
|
|
IL324479A
(en)
|
2023-05-15 |
2026-01-01 |
Genmab As |
Methods for treating CD20-expressing B-cell cancers
|
|
WO2024236031A1
(en)
|
2023-05-15 |
2024-11-21 |
Genmab A/S |
Highly purified epcoritamab compositions
|